Multiple studies [8–11] have shown that the clinical outcome of adjuvant TAM is influenced by the CYP2D6 genotype since poor metabolizers (PMs) have a higher risk of breast cancer recurrence than normal metabolizers (NMs). This evidence concerns the gene CYP2D6 and breast carcinoma.